Sitemap | Kontakt | Impressum
Sprachen English Deutsch

Kundenkonto

E-Mail-Adresse:

Passwort vergessen?

Warenkorb

Sie haben noch keine Artikel in Ihrem Warenkorb.

Alle Produktinformationen und -preise können jederzeit Änderungen unterliegen.

Neue Artikel

Rosai and Ackerman's Surgical Pathology

Goldblum, Lamps, McKenney, Myers

Rosai and Ackerman's Surgical Pathology


Online-Streitbeilegungs-plattform

Die EU-Kommission hat gemäß EU-Verordnung Nr. 524/2013 eine interaktive Website (OS-Plattform) bereit gestellt, die der Beilegung außergerichtlicher Streitigkeiten aus Online-Rechtsgeschäften dient. Die OS-Plattform der EU-Kommission finden Sie unter diesem Link: ec.europa.eu/consumers/odr/.
[<<Erstes] | [<zurück] | [weiter>] |  [Letztes>>] |  116 Artikel in dieser Kategorie

Hall, Hall

Cutaneous Drug Eruptions

Diagnosis, Histopathology and Therapy

Cutaneous Drug Eruptions

September 2015

Hardcover, 463 p., 213 ill.

Verlag: Springer

ISBN: 978-1-4471-6728-0

Statt 149,79 EUR
Nur 123,04 EUR

inkl. 7 % MwSt.

Special offer from the publisher from July 1, 2017 until October 31, 2017
Delivery times between 2 and 14 days from when you complete the order.

The burden of cutaneous drug reactions is significant, in both outpatient and inpatient settings, and can result in morbidity and even mortality. This book is unique in its approach to this problem.  This text is divided into basic principles, common drug reactions, skin conditions mimicked by drug reactions, drug reactions to the skin appendages, life-threatening drug reactions, less common drug reactions, and special groupings of drug reactions. For the clinician, the skin can only morphologically react in to many limited ways. This is also true for the pathologist. Combining these two forever linked specialties is a synergistic paradigm that greatly enhances diagnosis, and ultimately therapy, for these pernicious conditions. Drug reactions in the skin remain a common complication of therapy. True incidences of drug reactions are not available. For general discussion, the rule of 3% can be applied with reasonable assuredness. Approximately 3% of all hospitalized patients develop an adverse cutaneous drug reaction. Approximately 3% of these reactions are considered severe. Outpatient data is even more obscure, but at least 3% of dermatology clinic outpatient visits are due to a drug reaction. Cutaneous drug reactions compromise approximately 3% of all drug reactions. Even more challenging is the fact that the most vulnerable populations to drug reactions are increasing and include the elderly patients on prolonged drug therapy, and patients that use multiple drugs at the same time.